For example, considering ethnicity and AD clinical presentation, the role of the Th17 axis plays a greater role in the chronic phase of AD, and to a greater extent in intrinsic AD forms, in children and in patients of Asian ethnicity, where JAK1 inhibitors and/or anti-IL17, anti-IL-23, anti-IL-22 immunobiologicals may in the future prove to be an alternative to first-line therapeutic agents or in refractory cases. Here, JAK1 is linked to Alzheimer disease.